Commercializing Continuous Processing in Pharma
Safety, Efficacy, Efficiency and Quality: Scaling Your Continuous Processing from Technology to Commercial Manufacturing
Four years in the drug development world isn’t long, and the progress made in continuous processing has been an extraordinary. Thanks to the encouragement of the FDA and maturing technology; both pharma and biotech are starting to adopt continuous manufacturing (CM) in a commercial setting.
Over the last 12 months we have seen major milestones in continuous manufacturing globally – PROSPECT project in the UK, GSK’s announcement of CM facilities in Singapore, Merck has filed an NDA under CM approach, Bill and Melinda Gates Foundation granted $14.3m to Univercells to deploy CM for measles and rubella vaccine continuous manufacturing.
At the 4th Annual CCP Summit we will continue to explore scientific and technology advancements that can help eliminate bottlenecks, and more importantly, will address the quality, upfront investment and business rationale behind the ‘switch’.
Returning to Boston for the 4th time on Jan 28 – 30, 2020 – Get involved now!
Industry Pricing - Conference Only - Early birds are available: USD 2899.00
Industry Pricing - Conference + Workshop Day - Early birds are available: USD 3797.00
Industry Pricing - Conference + 1 Workshop - Early birds are available: USD 3398.00
Vendor Pricing - Conference Only - Early birds are available: USD 3799.00
Vendor Pricing - Conference + Workshop Day - Early birds are available: USD 4697.00
Vendor Pricing - Conference + 1 Workshop - Early birds are available: USD 4298.00
Speakers: Manuel Osorio, Senior Scientist and Program Lead for Emerging Technologies, FDA/CBER, Ganapathy Mohan, Executive Director, Head of External Affairs (Quality), Merck and Co., Inc., Justin Moser Director – Advanced Manufacturing Technology Merck and Co., Inc., Malcolm Berry, Founder, mbchemistryconsulting, Jana Spes, Head of Pharmaceutical Development and Manufacturing Sciences, Ironwood Pharmaceuticals, Jon-Paul Sherlock, Global Technology Strategy Director, AstraZeneca, Nick Thomson, Senior Director, Chemical Research and Development, Pfizer Inc., Sune Klint Anderson, Principal Scientist in Particle Engineering, Janssen RandD, Atul Dubey, Director, Pharmaceutical Continuous Manufacturing, US Pharmacopeia, Lawrence de Belder, Senior Principal Engineer, Janssen, Carla Luciani, Group Leader of Future Manufacturing Innovation, Associate Engineering Advisor, Eli Lilly and Co., Marcus Fiadeiro, Associate Director, Continuous Manufacturing, Sanofi, Bradley Campbell, Research Scientist, Eli Lilly and Co., Klaus Kaiser, Head Downstream Development, Product Supply, Pharmaceuticals, Bayer AG, Joon Chong Yee, Associate Director, Upstream Process Development, Codiak BioSciences, James Angelo, Scientist II, Bristol Myers-Squibb, Elçin Içten-Gençer, Senior Engineer, Pivotal Drug Substance Process Development, Amgen, Kaid Harper, Senior Scientist, AbbVie, Daniel Milano, Senior Engineer, Conjugation Process Development, ImmunoGen, Dave Berry, Manager of Complex Particles, CPI UK, Nathan Domagalski, Senior Principal Scientist, Pfizer Inc., Ru Zang, Associate Director, Mersana Therapeutics, Thomas de Beer, Head of Laboratory of Pharmaceutical Process Analytical Technology, University of Ghent, Lisa Graham, VP, Analytics Engineering, Seeq, Bob Lenich, Director, Life Sciences Business, Emerson, Miguel Gonzalez, Senior Director, Chemical Engineering, Asymchem, Hans Johansson, Global Applications Director, Life Sciences, Purolite, Thomas Erdenberge, Process Development Consultant, Sartorius Stedim Biotech, Ian Leavesley, President, Modern Consulting, LLC, Ernie Hillier, Founder, EJH Consulting